Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd. has recently undergone a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions amid a challenging pharmaceutical sector landscape, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now presenting a more compelling investment case relative to peers and historical averages.

Alembic Pharmaceuticals Ltd. reported a mixed performance in Q1 FY27, with consolidated net profit standing at ₹173.07 crores, representing a sequential decline of 14.62% from Q4 FY26 but a year-on-year improvement of 12.11%. The Vadodara-based pharmaceutical manufacturer, with a market capitalisation of ₹15,928 crores, delivered robust top-line growth with net sales surging 25.66% year-on-year to ₹2,149.77 crores, marking the highest quarterly revenue in the company's recent history. However, the stock has struggled to gain investor confidence, declining 16.30% over the past year whilst the broader pharmaceuticals sector rallied 17.87%, resulting in a significant underperformance of 34.17 percentage points.

Alembic Pharmaceuticals Ltd. is rated Sell by MarketsMOJO. This rating was last updated on 20 July 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 01 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 August 2026, providing investors with the most up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

Alembic Pharmaceuticals Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 20 Jul 2026. This decision follows a comprehensive reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite some attractive valuation metrics, the downgrade reflects concerns over flat recent financial performance, deteriorating technical indicators, and subdued long-term growth prospects.

Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite a modest day gain of 1.97%, the stock’s technical indicators present a complex picture, with weekly signals showing bullish tendencies while monthly metrics suggest caution. This nuanced technical landscape warrants a detailed analysis for investors navigating the Pharmaceuticals & Biotechnology sector.

Alembic Pharmaceuticals Ltd. has seen its investment rating upgraded from Sell to Hold as of 15 July 2026, reflecting a nuanced improvement across technical indicators, valuation metrics, and financial trends despite some lingering challenges in long-term growth. The company’s stock price has gained momentum recently, supported by a more stable technical outlook and attractive valuation compared to peers, prompting a reassessment of its investment potential within the Pharmaceuticals & Biotechnology sector.

Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical parameters, moving from a mildly bearish trend to a sideways momentum. This transition is reflected in a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, signalling a cautious outlook for investors amid recent price gains.

Alembic Pharmaceuticals Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a recent downgrade from Hold to Sell by MarketsMOJO on 8 July 2026, the stock exhibits a complex interplay of bullish and bearish signals across various technical indicators, warranting a detailed analysis for investors navigating this evolving landscape.

Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively paint a nuanced picture of the stock’s near-term prospects amid a challenging sector environment.

Alembic Pharmaceuticals Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 8 July 2026. This shift reflects a combination of deteriorating technical indicators, flat financial performance, and subdued long-term growth prospects, despite some attractive valuation metrics and strong institutional backing.

Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively paint a nuanced picture of the stock’s near-term prospects amid a challenging market environment.

Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend as of early July 2026. Despite a modest day decline of 0.41%, the stock’s technical indicators present a complex picture, with weekly signals showing mild bullishness while monthly trends remain cautious. This nuanced technical landscape warrants a detailed analysis for investors seeking clarity on the stock’s near-term trajectory.

Alembic Pharmaceuticals Ltd. has experienced a nuanced shift in its technical momentum, with indicators signalling a transition from sideways to mildly bearish trends. Despite a recent day gain of 1.44%, the stock’s technical landscape presents a complex picture, combining bullish and bearish signals across weekly and monthly timeframes, prompting a cautious stance among investors.

Alembic Pharmaceuticals Ltd. has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical outlook and valuation metrics. Despite recent flat financial performance and a challenging one-year return, the company’s enhanced technical indicators and attractive valuation relative to peers have prompted a reassessment of its investment potential.